Human papillomavirus testing in patients with invasive cervical carcinoma: An institutional experience

Journal of the American Society of Cytopathology

Volumn 3, Issue 3, 2014, Pages 126-130

  Can, Nhu Thuy ^a   Tesic, Vera ^a   Antic, Tatjana ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cervix; Co testing; Human papillomavirus; Invasive carcinoma; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FALSE NEGATIVE RESULT; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INVASIVE CARCINOMA; MIDDLE AGED; PAPANICOLAOU TEST; PRIMARY TUMOR; PRIORITY JOURNAL; REPEAT PROCEDURE; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 84899814214     PISSN: 22132945     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jasc.2014.01.001     Document Type: Article

References (18)

1. Cohen D., Austin R.M., Gilbert C., Freij R., Zhao C. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results. Am J Clin Pathol 2012, 138:517-523.
2. Jastania R., Geddie W.R., Chapman W., Boerner S. Characteristics of apparently false-negative Digene Hybrid Capture 2 high-risk HPV DNA testing. Am J Clin Pathol 2006, 125:223-228.
3. Kulmala S.M., Syrjänen S., Shabalova I., et al. Human papillomavirus testing with the Hybrid Capture 2 assay and PCR as screening tools. J Clin Microbiol 2004, 42:2470-2475.
4. Naryshkin S., Austin R.M. Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug, Healthc Patient Saf 2012, 4:167-172.
5. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137:516-542.
6. Stoler M.H., Castle P.E., Solomon D., Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007, 127:335-337. American Society for Colposcopy and Cervical Pathology.
7. Yamazaki H., Sasagawa T., Basha W., Segawa T., Inoue M. Hybrid Capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer 2001, 94:222-227.
8. Zhao C., Weng B., Li Z., Yang H., Austin R.M. Follow-up outcomes of a large cohort of low-risk women with negative imaged liquid-based cytology and negative HPV test results. Am J Clin Pathol 2013, 139:32-38.
9. Cuzick J., Cadman L., Mesher D., et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013, 108:908-913.
10. Katki H.A., Kinney W.K., Fetterman B., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12:663-672.
11. Sherman M.E., Wang S.S., Wheeler C.M., et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003, 12:1038-1044.
12. Crum C.P., Nagai N., Levine R.U., Silverstein S. In situ hybridization analysis of HPV 16 DNA sequences in early cervical neoplasia. Am J Pathol 1986, 123:174-182.
13. Garner-Hamrick P.A., Fisher C. HPV episomal copy number closely correlates with cell size in keratinocyte monolayer cultures. Virology 2002, 301:334-341.
14. Schneider A., Oltersdorf T., Schneider V., Gissmann L. Distribution pattern of human papilloma virus 16 genome in cervical neoplasia by molecular in situ hybridization of tissue sections. Int J Cancer 1987, 39:717-721.
15. Eltoum I.A., Chhieng D.C., Crowe D.R., Roberson J., Jin G., Broker T.R. Significance and possible causes of false-negative results of reflex human papillomavirus infection testing. Cancer 2007, 111:154-159.
16. Boulet G.A., Benoy I.H., Depuydt C.E., et al. Human papillomavirus 16load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or = 2 in a liquid-based cytology setting?. Cancer Epidemiol Biomarkers Prev 2009, 18:2992-2999.
17. Ko V., Tambouret R.H., Kuebler D.L., Black-Schaffer W.S., Wilbur D.C. Human papillomavirus testing using Hybrid Capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer 2006, 108:468-474.
18. Austin R.M., Zhao C. How should "negative" laboratory developed test results for human papillomavirus be verified?. Am J Clin Pathol 2012, 138:619-620.